Many cancer cells exhibit increased rates of uptake and metabolism of glucose compared with normal cells. Glucose uptake in mammalian cells is mediated by the glucose transporter (GLUT) family. Here, we report that DNA-damaging anticancer agents such as Adriamycin and etoposide suppressed the expression of GLUT3, but not GLUT1, in HeLa cells and a tumorigenic HeLa cell hybrid. Suppression of GLUT3 expression determined by the real-time PCR was also evident with another DNA-damaging agent, camptothecin, which reduced the promoter's activity as determined with a luciferase-linked assay. The suppression by these agents seemed to be induced independently of p53, and it was evident when wild-type p53 was overproduced in these cells. In contrast, the mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) kinase (MEK) inhibitor U0126 (but not the phosphoinositide 3-kinase inhibitor LY294002) prevented the drug-induced suppression as determined by reverse transcription-PCR and promoter assays. Furthermore, overexpression of GLUT3 in HeLa cell hybrids increased resistance to these drugs, whereas depletion of the gene by small interfering RNA rendered the cells more sensitive to the drugs, decreasing glucose consumption. The results suggest that DNA-damaging agents reduce GLUT3 expression in cancer cells through activation of the MEK-ERK pathway independently of p53, leading to cell death or apoptosis. The findings may contribute to the development of new chemotherapeutic drugs based on the GLUT3-dependent metabolism of glucose.
Introduction
Many cancer cells use nutrients such as glucose as a source of energy for growth and survival (1) (2) (3) . Cancer cells prefer to metabolize glucose by aerobic glycolysis instead of oxidative phosphorylation, a phenomenon termed as the Warburg effect (4). Increased glucose uptake in cancer cells can be measured clinically by [ 18 F]deoxyglucose positron emission tomography (5, 6) .
The glucose transporter (GLUT) mediates facilitated uptake of D-glucose in mammalian cells. The GLUT family has >10 members, all expressed in a tissue-specific manner (7) . GLUT1 is widely expressed in all proliferating cells, whereas GLUT3 is predominantly expressed in neuronal cells (7) . Both isoforms show high affinity for D-glucose under normal physiologic conditions (8, 9 ). An upregulation of GLUT1 or GLUT3 expression is observed in many tumors, such as gliomas, non-small cell lung carcinomas, gastroenterologic tumors, and ovarian carcinomas (10) (11) (12) (13) (14) (15) (16) . The increased glucose uptake correlates with the level of expression of GLUTs in the plasma membrane (17, 18) . Because expression of the GLUT family often shows a strong association with malignancy (14) , the components controlling their expression could be important as targets for cancer therapy as well as for the early diagnosis of tumors and as molecular markers of malignancy (1) .
We have previously reported a tumor-associated alteration of GLUT1 or GLUT3 in human cell hybrids derived from cervical carcinoma HeLa cells and normal fibroblasts (19) (20) (21) . The tumorigenic hybrid (CGL4) expressed both GLUT1 and GLUT3, whereas the tumor-suppressed hybrid (CGL1) expressed GLUT1 alone (21) . This tumorassociated GLUT3 expression is regulated at the level of transcription at least (21) .
The regulation of GLUT3 transcription is associated with several signaling molecules such as the nuclear factors Sp1 and cyclic AMP in rodent cells. In rat neurons, Sp1 and Sp3 regulated GLUT3 expression and bound to cis elements in the promoter (22, 23) . In mouse muscle cells, insulin-like growth factor-I played a role in maintaining GLUT3 expression via Sp1 (24) . The mouse GLUT3 promoter also responded to cyclic AMP in a breast cancer cell line (25) . However, human GLUT3 expression during tumorigenesis has not been extensively studied.
It is also known that genotoxic stress-induced signals regulate GLUT3 expression. Multiple genotoxic stimuli such as Adriamycin (ADR), etoposide (ETOP), cisplatin, UV, and γ-radiation resulted in a suppression of GLUT3 expression and glucose metabolism (26) and also initiated cell death pathways (27) . However, the role of GLUT3 in cell survival remains unclear.
A well-known tumor suppressor, p53, plays an important role in the response to DNA damage (28) . The p53 protein is mainly degraded by Mdm2-mediated ubiquitindependent proteolysis and is kept at low levels in vivo (29) . In response to DNA damage, stabilization of p53 is mediated by the ATM and ATR protein kinases (27, 28) . The stabilized p53 promotes cell cycle arrest to allow repair or the initiation of apoptosis (27, 28) .
Recent studies have highlighted a link between p53-mediated surveillance of damaged DNA and the metabolism of glucose. Kawauchi et al. (30) , using p53-null mouse embryonic fibroblasts (MEF), showed that the expression of GLUT3 is regulated through NF-κB in a p53-dependent manner. Although the p53 protein plays a critical role in responses to DNA damage, p53-independent responses to DNA damage have also been reported (31) (32) (33) (34) . Damage to DNA activates extracellular signal-regulated kinase (ERK) pathways in parallel with p53 in an ATM-dependent manner. The ERK activation associated with DNA damage mediates cell cycle arrest and apoptosis (33) .
Here, we report that DNA-damaging agents such as ADR and camptothecin (CPT) suppressed the expression of GLUT3 at a transcriptional level in HeLa cells and human cell hybrids. The levels of mRNA were quantitatively and statistically determined by the real-time PCR method. We also show that this suppression occurred independently of p53 and mainly involved the activation of ERK. We show that the level of GLUT3 expression was linked to DNA damage-induced cell death. Our data indicate that GLUT3 plays a key role in the surveillance of DNA damage in human tumor cells.
Materials and Methods

Antibodies, reagents, and RNA interference
The mouse monoclonal antibody to β-actin was purchased from Sigma, whereas those to human p21, phosphorylated ERK1/2 and ERK1, were from BD Biosciences and human p53 was from Santa Cruz Biotechnology. An enhanced chemiluminescence kit was obtained from GE Healthcare. Lipofectamine 2000 reagent and small interfering RNAs (siRNA) to p53 (HSS186390), ERK1 (VHS40318), and GLUT3 (HSS143955) were purchased from Invitrogen. ADR, ETOP, CPT, vinblastine, paclitaxel, U0126, and LY294002 were obtained from Calbiochem. Nutlin-3 and cisplatin were obtained from Sigma.
Cell culture and transfection
HeLa-S3 and Caco-2 were obtained from the American Type Culture Collection. CGL4 was previously established as a tumorigenic derivative of the parental tumorsuppressed cell hybrid ESH5 from HeLa D98/AH2 cells and normal human fibroblasts (19) (20) (21) (35) (36) (37) . HeLa-S3 and CGL4 were cultured in DMEM (Invitrogen) containing 5% fetal bovine serum (MBL), and Caco-2 was cultured in DMEM containing 10% fetal bovine serum, supplemented with penicillin (100 units/mL) and streptomycin (100 μg/mL) under humidified 5% CO 2 /95% air at 37°C, as described previously (21) . These cells were free from mycoplasmic contamination. One day before the transfection, the cells were trypsinized and seeded onto six-well plastic culture plates (Asahi Glass). On the following day, transfection procedures were done using 6 μL of Lipofectamine 2000 diluted in 250 μL of DMEM (Sigma) and 1 μg of DNA diluted in 250 μL of supplementary DMEM in the six-well plates. Cells were incubated in the presence of the lipofectamine/DNA complex for 24 hours at 37°C in 5% CO 2 . At 24 hours posttransfection, cells were used for luciferase assays or immunoblotting as described below.
Reverse transcription-PCR
Total RNA was extracted using TRIzol (Invitrogen). cDNA was prepared using oligonucleotides (dTs; Invitrogen) and Superscript III (Invitrogen). Reverse transcription-PCR (RT-PCR) analyses of GLUT1, GLUT3, p21, and p53 or β-actin as a control were carried out using the following primer pairs: GLUT1, 5′-AAGTCCT-TTGAGATGCTGATCCT-3′ forward and 5′-AA-GATGGCCACGATGCTCAGATA-3′ reverse; GLUT3, 5′-AACCAGCTGGGCATCGTTGTTGG-3′ forward and 5′-GCCACAATAAACCAGGGAATGGG-3′ reverse; p21, 5′-GGATGTCCGTCAGAACCCAT-3′ forward and 5′-CCAGCACTCTTAGGAACCTCT-3′ reverse; p53, 5′-CCACCATGAGCGCTGCTCA-3′ forward and 5′-GCAGGGGAGGGAGAGATG-3′ reverse; β-actin, 5′-TTAAGGAGAAGCTGTGCTACGTC-3′ forward and 5′-AGGAGCAATGATCTTGATCTTCA-3′ reverse. β-Actin was used as a loading control.
Quantitative real-time PCR analysis
This was done using a TaqMan Universal Master Mix II (Applied Biosystems) under the following conditions: 15 minutes at 95°C followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute using a 7500 realtime PCR system (Applied Biosystems). The predesigned primer and probe sets for human GLUT1, GLUT3, and β-actin are commercially available (Applied Biosystems; GLUT1, Hs00892681_m1; GLUT3, Hs00359840_m1; β-actin, Hs99999903_m1). Threshold cycle (C t ) values were automatically calculated for each replicate and used to determine the relative expression of the gene of interest relative to reference genes for both treated and untreated samples by the 2 −ΔΔCt method.
Plasmids
The full-length wild-type (wt) human p53 was cloned into a pCDNA3.1+ vector (Invitrogen). A p53 mutant (L14Q/ F19S), unable to bind DNA (38) , was generated by two-step mutagenesis (Stratagene) using pCDNA-p53 wt as a template. PCR products were sequenced to confirm that sequences were correct. Mutant p53 cDNA was subcloned into pCDNA3.1+ to generate pCDNA3-p53 (L14Q/F19S). Full-length human GLUT1 and GLUT3 promoter-reporter constructs (GLUT1-P-Full and GLUT3-P-Full) were generated by subcloning of the upstream 5′ region of the human GLUT1 (−3,057 to +1) or GLUT3 (−2,788 to +1) gene into pGL4.10 (Promega) upstream of the firefly luciferase gene. Sequential 5′ deletion mutants of the GLUT1 and GLUT3 promoter were generated by the digestion of GLUT1-P-Full or GLUT3-P-Full with suitable restriction endonucleases, followed by ligation. The control plasmid pGL4.74 (Renilla luciferase reporter) was also obtained from Promega. The NH 2 terminal EGFP-GLUT3 (GFP-G3) cDNA construct was described previously (39) .
Immunoblotting
Cells were cultured in DMEM plus 5% (v/v) fetal bovine serum (MBL) overnight. After transfection or the addition of appropriate inhibitors, the cells were incubated for another 24 hours. They were then harvested and lysed in lysis buffer [20 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1.0 mmol/L dithiothreitol, 20 mmol/L glycerophosphate, 2 mmol/L Na 3 VO 4 , 1% NP40, and 1 mmol/L phenylmethylsulfonyl fluoride]. The whole-cell lysate was electrophoresed on a 10% SDS-PAGE gel, transferred to polyvinylidene difluoride membranes, and immunoblotted with the antibody. β-Actin was used as a loading control. The intensity of bands was quantified with ImageJ (Wayne Rasband, NIH).
Transcriptional reporter assays
For the GLUT promoter-luciferase assay, CGL4 cells were cotransfected with either GLUT promoter-Luc or vector plasmids (pGL4.10) and pGL4.74 as an internal control for the transfection rate. A dual-luciferase assay kit (Promega) was used according to the manufacturer's directions. The activity levels were expressed relative to a vector control.
Cell viability analysis
Cell viability was determined with Cell Counting Kit-8 -(Dojindo) as described previously (40) . Briefly, cells (2.5 × 10 3 for CGL4 and CGL4/gt3) were plated onto 96-well plates and treated with the appropriate inhibitor as indicated in figure legends. After incubation at 37°C in 5% CO 2 /95% air for 72 hours, cell viability was calculated relative to the DMSO control.
Measurements of glucose consumption
Cells were seeded in six-well dishes, and the medium changed after an overnight culture. Cells (∼90% confluent) were incubated for 24 hours, and then the culture medium was collected for measurements of glucose concentrations using a Glucose (GO) Assay kit (Sigma). Glucose consumption was calculated from a standard curve.
Statistical analysis
The statistical significance of differences in data was determined using the unpaired Student's t test. A P value of <0.01 or <0.05 was considered statistically significant.
Results
DNA-damaging agents suppress GLUT3 mRNA accumulation in HeLa cells
Previously, we have reported that the tumorigenic HeLa cell hybrid CGL4 expressed GLUT1 and GLUT3, whereas a tumor-suppressed hybrid, CGL1, expressed GLUT1 alone (21, 35) . The increased glucose uptake by the tumorigenic cells was well associated with the level of GLUT3 expression (21) . To search for drugs to suppress GLUT3 expression in CGL4 cells, we analyzed the effect of ADR in HeLa and CGL4 cells by RT-PCR (Fig. 1A) . Inhibition was obtained in a dose-dependent manner, consistent with the inhibition of cell growth (Supplementary Fig. S1 ; Fig. 5D ). The accumulation of GLUT3 mRNA was further quantitated by the real-time PCR method and was shown to be reduced by ∼30% by treatment with ADR (0.5 μg/mL) for 24 hours. In contrast, the expression of GLUT1 was not suppressed by vehicle (−) or ADR (+) treatment (Fig. 1A) , and a small increase in GLUT1 expression with ADR was observed, suggesting the effects of ADR on GLUTs to be more selective between GLUT3 and GLUT1.
We also tested other DNA-damaging agents such as ETOP and CPT. As expected, the expression of p21 was upregulated after treatment with each of these agents (Fig. 1B) . ETOP (50 μmol/L) or CPT (250 nmol/L) like ADR (0.5 μg/mL) reduced the amount of GLUT3 mRNA accumulated (Fig. 1B) . These effects were also dose dependent ( Supplementary Fig. S1 ). Although ETOP and ADR did not affect GLUT1 expression, CPT inhibited it (Fig. 1B) . A small increase in GLUT3 expression was observed on exposure to nutlin-3 (25 μmol/L), a small molecular antagonist for the p53-binding protein MDM-2, despite that nutlin-3 upregulated p21 expression and accumulation of p53 to almost the same extent as the other DNA-damaging agents (Fig. 1C) . These results suggest that the HeLa and CGL4 cell lines are capable of responding to nutlin-3 to accumulate p53 protein and upregulate p21 expression.
The suppressive effect on GLUT3 expression of these DNA-damaging agents was preserved because it was not evident on treatment with non-DNA-damaging and microtubule-attacking agents such as vinblastine (100 nmol/L) or paclitaxel (1 μmol/L; Fig. 1D ), which inhibited cell growth (Supplementary Table S1 ; data not shown).
GLUT3 promoter activity was suppressed by treatment with CPT and cisplatin
Because DNA-damaging agents suppressed GLUT3 expression, we next determined whether this is reflected to some extent by a reduction in promoter activity. We conducted transient transfection/luciferase assays using a reporter plasmid containing either full-length GLUT1 or GLUT3 promoter-luciferase (GLUT1-P-Full or GLUT3-P-Full) as well as a series of truncated constructs as outlined in Fig. 2A or B. These plasmids, GLUT1-P-Full and GLUT3-P-Full, were shown to be suitable for transfection into CGL4 cells, as shown by high levels of dualluciferase activity (gray bars in Fig. 2A and B) . Shortening of the promoter of GLUT3 was shown to reduce the level of activity, indicating the presence of positive elements (Fig. 2B) . In contrast, truncation of the promoter of GLUT1 caused an ∼2-fold increase in activity compared with the full-length promoter. This suggests the existence of negative regulatory elements between −3,057 and −534.
Treatment of the plasmid-transfected cells with CPT at 250 nmol/L reduced GLUT3 or GLUT1 promoter activity by quarter to half (open bars in Fig. 2A and B) , consistent with the results of RT-PCR (Fig. 1B) . Another DNA-damaging agent, cisplatin, also suppressed GLUT3 promoter activity, consistent with the results of RT-PCR ( Supplementary Fig. S2 ). It was noted that the smallest segments of GLUT1-P-K-luc and GLUT3-P-#4-luc were responsible for CPT, indicating the response elements for the CPT-induced DNA damage to be located between −534 and 1 (GLUT1-P) and −668 to 1 (GLUT3-P). The effects of ADR and ETOP on the promoter activities could not be determined under the conditions, because addition of these drugs to the assay system interfered with the chemiluminescence from luciferase. Consistent with results of RT-PCR (Fig. 1B and D) , nutlin-3 showed no suppressive effect and induced a small increase in the GLUT3 promoter activity, but vinblastine did not ( Supplementary Fig. S3 ).
ADR-induced suppression of GLUT3 expression is independent of p53
Previously in MEFs, GLUT3 mRNA levels increased on depletion of p53 by siRNA (30) . In the present study, however, the inhibition of GLUT3 expression by ADR or other DNA-damaging agents occurred independent of p21 expression, which seems to be dependent on p53 (Fig. 1B and C) . We next examined whether or not knockdown of p53 affects the ADR-induced suppression of GLUT3 expression in CGL4 cells. p53 protein was temporarily depleted in CGL4 cells by adding siRNA, whose concentration was also enough to lower the levels of p53 protein raised by ADR treatment (Fig. 3A) . Under these conditions, the GLUT3 expression in CGL4 cells was not significantly affected by p53-siRNA (Fig. 3B) . In addition, it was suppressed by ADR in the p53-depleted CGL4 cells (Fig. 3B) . In accordance with this result, the basal level of activity of the GLUT3 promoter was not greatly affected by the depletion and was suppressed by CPT in the p53-depleted cells (Fig.  3C) . The results further support the idea that DNAdamaging agents suppress GLUT3 expression independently of p53.
Because it has been reported that p53 downregulates GLUT1, GLUT3, and GLUT4 expression in SaOS-2, RD, and C2C12 cells and MEFs (30, 41), we next examined the direct effect of p53 on GLUT3 expression in the CGL4 cell lines. CGL4 cells were transfected with either the wt-p53 cDNA (Wt) or the p53-inactivated mutant cDNA (Mt). A lower level of p53 protein was detected in the control vector-transfected cells (Fig. 3D) . Significantly, higher levels of p53 protein and p21 protein were observed in wt-p53 transfected cells, consistent with changes in the mRNA (Fig. 3D and E) . However, no overproduction of p21 protein or mRNA was obvious in the cells transfected with mt-p53 (Fig. 3D) . Under these conditions, GLUT3 expression at the levels of mRNA (Fig. 3E ) and protein (data not shown) was unaffected. Thus, these results indicate that wt-p53 does not directly control GLUT3 expression in CGL4 cell lines. Transfection of CGL4 cells with wt-p53 did not affect the promoter activity detected by GLUT3-P-Full, and a reduction due to CPT was observed (Fig. 3F) . In addition, the suppression of GLUT3 expression by treatment with ADR was observed in Caco-2 cells (Supplementary Fig. S4 ), which is reported as a p53-null colonic carcinoma (42) .
MEK inhibitor, U0126, blocks ADR-induced suppression of GLUT3 expression
Because damage to DNA induces activation of ERK in several cell lines in a p53-independent manner (33), we investigated whether the activation plays a role in the DNA damage-induced suppression of GLUT3 FIGURE 2. Dissection of human GLUT1 or GLUT3 promoter response elements. Left, a promoter map of the GLUT1 (A) or GLUT3 (B) gene and sequential deletions of promoter regions. A, "Full" contains the full-length promoter, whereas "SE" and "K" contain a series of deleted GLUT1 promoters. B, "Full" contains the full-length promoter, whereas "S1-4," "SX," and "#4" contain a series of deleted GLUT3 promoters. "Luc" represents the luciferase reporter gene. The transcription start site is indicated by +1. The locations of the 5′ ends of the promoters are indicated by the negative numbering of nucleotides relative to the start site. The graphs to the left display luciferase activity. Transient transfection and luciferase assays of GLUT promoter reporter plasmids were done. CGL4 cells were cotransfected with the luciferase reporter plasmid and pGL4.74. At 6 h after transfection, cells were treated with CPT (250 nmol/L) or DMSO for 24 h. The luciferase units produced by transfected cells treated with DMSO (gray columns) and CPT (open columns) are plotted. Data are the mean ± SD for three independent experiments. *, P < 0.01 for the indicated comparison (t test).
expression. DNA-damaging agents induced phosphorylation of ERK in HeLa cells, and this was completely suppressed by the MEK inhibitor U0126 (Fig. 4A ). Although U0126 alone had little effect on GLUT3 expression (Fig. 4B) , the ADR-induced suppression was restored on addition of U0126 in HeLa cells (Fig. 4B) . The downregulation of ERK1 protein production caused by adding siRNA also partly restored the ADR-induced suppression of GLUT3 expression (Supplementary Fig. S5 ). In a control experiment, LY294002 (LY), a selective phosphoinositide 3-kinase inhibitor, had little effect in ADR-treated or untreated cells (Fig. 4B) .
It is clear that the induction of p21 expression by ADR was not impaired by the treatment with U0126 or LY294002 (Fig. 4B) , suggesting that a signaling pathway for p21 production is operating in the presence of these inhibitors. The effect of a MEK inhibitor on GLUT3 expression was further examined with the promoter assay. The level of activity of the GLUT3 promoter reduced by CPT in CGL4 cells using three types of reporter plasmid (GLUT3-P-Full, S1-4 or #4) was also restored by U0126 (5 μmol/L; Fig. 4C ), whereas there was little or no effect on the CPT-induced suppression of the GLUT1 promoter (Fig. 4D) . 
GLUT3 contributes to resistance against genotoxic stress
Because a signaling pathway via MEK-ERK is thought to be involved in ADR-induced cell death, we next assessed the role of GLUT3 in cell death induced by DNA-damaging agents in CGL4. We have previously constructed transfectants (CGL4/gt3) that stably overexpressed GLUT3 in CGL4 cells (21) . Although GLUT3 mRNA levels declined during storage in liquid nitrogen, they remained ∼5-fold higher than those in the parental CGL4 cells (Fig. 5A and B) . In contrast, the expression of GLUT1 was comparable between these cell lines (Fig. 5B) . Greater consumption of glucose was also noted in CGL4/gt3 compared with CGL4 (Fig. 5C) . We have compared the effect of ADR on the growth of these cells in vitro by treating them with various amounts of ADR for 3 days. As shown in Fig. 5D , ADR had a dose-dependent effect on cell survival. The IC 50 value of ADR for CGL4 cells was 9.8 ± 1.3 ng/mL, but CGL4/gt3 cells were more resistant with IC 50 s of 17.9 ± 1.0 ng/mL (Supplementary Table S1 ). Similar drug resistance among GLUT3-expressing cells was seen for CPT but not vinblastine (Supplementary Table S1 ). We also found that overexpression of GLUT3 gene in CGL4 cells increased glucose consumption, rendering the cells more resistant to ADR-induced cell death (Supplementary Fig. S6 ).
To further examine the relationship between drug resistance and GLUT3 expression, we determined how knockdown of the GLUT3 gene affects sensitivity to ADR in CGL4 or CGL4/gt3 cells. GLUT3 mRNA was temporarily depleted in CGL4 and CGL4/gt3 cells by adding siRNA (Fig. 6A) . Incorporation of GLUT3 siRNA Research.
on September 24, 2017. © 2010 American Association for Cancer mcr.aacrjournals.org Downloaded from had no significant effect on the viability of CGL4 and CGL4/gt3 cells ( Fig. 6B and C) . In both types of cell, knockdown of GLUT3 decreased glucose consumption and sensitized the cells to ADR-induced death (Fig. 6B-D) , indicating that the level of GLUT3 expression is directly linked to cell damage induced by DNAdamaging agents.
Discussion
Different types of tumor cells show an increase in glucose uptake, which is often associated with elevated levels of GLUT family members such as GLUT1 and GLUT3 (14) (15) (16) . This characteristic has been exploited clinically for the detection of tumors by [ 18 F]deoxyglucose positron emission tomography (5, 6) . The downregulation of the expression of genes involved in glucose metabolism, including genes for GLUTs, may lead to a functional deficit in glucose consumption and cell growth. Hence, various antitumor drugs induce the death of tumor cells by activating apoptotic signaling pathways (27) . It has been recently reported that some antitumor agents that damage DNA through a variety of targets suppress the expression of GLUT genes (GLUT1 or GLUT3) and glucose uptake (26) . However, the mechanism by which these agents affect the gene expression of the GLUT family in human tumor cells and its role in cell death are largely unknown.
In this paper, we report novel findings on the response to DNA damage in cancer cells. Previous reports showed that treatment of cells with ADR, ETOP, or cisplatin led to GLUT3 suppression (26) . Our new observations result from detailed characterization of the mechanisms and consequences of GLUT3 suppression after ADR-induced DNA damage. We have mapped the activation of ERK to a point upstream of GLUT3 expression in response to DNA damage independent of p53 (Figs. 3 and 4) . Together with p53, such GLUT3 expression contributed to resistance against DNA damage-induced cell death (Figs. 5 and 6 ).
Because suppression of GLUT3 expression was found with ADR and ETOP (topoisomerase II inhibitor) as well as CPT (topoisomerase I inhibitor; Fig. 1B) , the damage to DNA by these inhibitors might be involved (26) . It has been proved that the molecular responses to these inhibitors by topoisomerases I and II are different (43, 44) . Indeed, ADR or ETOP was unable to suppress GLUT1 expression in HeLa or CGL4 cells, whereas CPT inhibited both GLUT1 and GLUT3 expression (Fig. 1B) . The molecular basis for the difference in suppression of GLUT1 and GLUT3 by these drugs seems to be an important subject for future study.
p53 has a role in the regulation of glycolysis through inhibition of the expression of the GLUTs directly as well as indirectly (30, 45) . In addition, p53 protein is also a major effector in the response to DNA damage (27, 28) . Therefore, it is essential to investigate any relationship between p53 and the inhibition of GLUT3. However, we found that the inhibition occurred independently of p53 in HeLa or HeLa cell hybrids in the case of the DNA damage response. This is based on the MDM2 inhibitor, nutlin-3, sustained p53 protein levels, and activated p21 expression but did not modulate GLUT3 expression ( Fig. 1B ; Supplementary  Fig. S1 ); the maximum level of GLUT3 suppression by ADR or CPT was not attenuated in p53-depleted cells (Fig. 3A-C) , and overexpression of wt-p53 did not prevent GLUT3 expression with activation of p21 expression ( Fig. 3D-E) . These findings strongly suggest that a p53-independent pathway is involved in the GLUT3 gene's suppression by DNA-damaging agents in these cell lines.
However, the present results are different from a previous report showing a link between GLUT3 expression and p53. Kawauchi et al. (30) showed that overexpression of wt-p53 led to GLUT3 suppression. Although there is a discrepancy among these results, this seems to be partly due to different cell types and signaling pathways. Kawauchi et al. studied MEFs, and we have used human-derived epithelial cancer cell lines (30) .
Although in various types of cells p53 protein plays an essential role in the response to DNA damage and apoptosis caused by DNA-damaging agents (27, 28, 46) , p53-deficient cells are not completely unable to undergo apoptosis (47) . Severe DNA damage could activate p53-independent apoptosis via backup systems. Because p53 is frequently mutated in tumors (48) , this backup system would clearly be important. In this study, we found the existence of a p53-independent signaling pathway to regulate the expression of GLUT3 in human carcinoma HeLa cells. This novel pathway may be involved in the apoptosis caused by anticancer agents in p53-mutated tumor cells. Our finding may provide another way to find anticancer drugs to trigger p53-independent DNA damage-induced apoptosis.
Although this p53-independent pathway remains largely unknown, we also found that the activation of ERK contributes to GLUT3 expression dependent on DNA damage, because the MEK inhibitor U0126 or ERK-siRNA prevented the ADR-or CPT-induced suppression of GLUT3 expression, and this coincided with the effects of CPT and U0126 on the promoter activity (Fig. 4) . These results are in line with the findings that DNA damageinduced apoptosis in NIH3T3 cells leads to activation of the MEK-ERK pathway in a p53-independent manner (33). The major cellular response to intense DNA damage is apoptosis (49) . DNA damage activates p53, which then induces apoptosis. Alternatively, DNA damage induced by genotoxic stress activates the MEK-ERK signaling pathway (33) , resulting in suppression of GLUT3 expression. The expression of GLUT3 is involved in resistance to cell death through an unknown mechanism.
It should also be noted that a scatter factor, a pleiotrophic cytokine, accumulates in tumors and prevents ADRinduced cell death through NF-κB activity (50) regulated by p53 (30) . These results may indicate that DNA damage activates both MEK-ERK and p53-NF-κB pathways leading to apoptosis. We have shown that GLUT3 expression makes important contributions to cell survival after DNA damage. Depletion of GLUT3 by siRNA enhanced sensitivity to ADR (Fig. 6) . Conversely, enforced expression of GLUT3 increased resistance to ADR in CGL4 cells ( Fig. 5; Supplementary Fig. S6 ). Thus, activation of the MEK-ERK signaling pathway may require suppression of GLUT3 expression, reducing glycolysis. It would be interesting to examine how GLUT3 controls the uptake and consumption of glucose and survival in tumor cells. In connection with this, it should be remembered that GLUT3 FIGURE 6 . Effect of depletion of GLUT3 using siRNA on DNA damage-induced cell death in CGL4 cells. A, GLUT3 expression in CGL4 or CGL4/gt3 cells transfected with control-or GLUT3-siRNA determined by RT-PCR (top) and quantitative real-time PCR (bottom). B and C, cultures of CGL4 or CGL4/gt3 were transfected with control-or GLUT3-siRNA. Cell numbers were quantified using a hematometer after treatment with ADR (62.5, 125, or 250 ng/mL) for 24 h. Cell numbers relative to the DMSO control (100% value) are plotted (left). D, glucose consumption in CGL4 or CGL4/gt3 cells transfected with control-or GLUT3-siRNA was measured (right). *, P < 0.01; **, P < 0.05, for the indicated comparison (t test).
and GLUT1 distribute to different microdomains in the plasma membrane, GLUT3 in a fluid domain and GLUT1 in raft-like domains (35, 39) .
Cancer cells show higher rates of glucose transport and glycolysis, and recent studies indicate the biological significance of this adaptation. Vaughn et al. showed that cancer cells inhibit cytochrome c-mediated apoptosis by a mechanism dependent on glucose metabolism (51). Schafer et al. also showed that detachment of mammary epithelial cells from the extracellular matrix causes reactive oxygen species-mediated apoptosis due to loss of glucose transport (52) . In addition, in human colon cancer cell lines, the upregulation of glucose uptake induced by endogenous KRAS or BRAF mutations was essential to survival under cytotoxic conditions (53) . These findings are consistent with our observation that the depletion of GLUT3 expression and glucose uptake cooperate to protect against genotoxic stress induced by ADR. These results may contribute to new developments for anticancer agents based on glucose metabolism.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
